Comparing infectious risk of Trastuzumab-deruxtecan to Trastuzumab-emtansine in patients with breast cancer - PubMed
4 days ago
- #infectious-risk
- #antibody-drug-conjugate
- #breast-cancer
- The study compares the infectious risk of Trastuzumab-deruxtecan (T-DXd) and Trastuzumab-emtansine (T-DM1) in breast cancer patients.
- T-DXd was associated with a higher incidence of infections (24.4% vs 14.0%) and more bloodstream infections (33.3% vs 5.9%) compared to T-DM1.
- Infection-related mortality and opportunistic infections were rare and only occurred in the T-DXd cohort.
- After adjusting for confounding variables, T-DXd was not significantly associated with an increased risk of infection (OR = 1.89, 95% CI: 0.85-4.32, p = 0.12).
- Future prospective studies are needed to evaluate the infectious risk of T-DXd, especially as it is used earlier in treatment.